# A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

> clinical trial · VERIFIED · 2026-07-02

Status: NOT_YET_RECRUITING · Sponsor: Bristol-Myers Squibb · Condition: Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

- Company: Bristol-Myers Squibb
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07680764

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.